Interestingly, although overexpression of FOXA1 is associated with poor prognosis in prostate cancer [55], ERα-positive breast cancer with high FOXA1 expression shows favorable sensitivity to endocrine therapy [56]. This evidence concerns the gene ESR1 and prostate cancer.